Oxford BioTherapeutics (Oxford)

Oncology Corporate Profile

HQ Location

94A Innovation Drive
Milton Park
Abigndon, UK, OXON OX14 4RZ

Company Description

Oxford BioTherapeutics is an international biotechnology company focused on developing innovative antibody drug conjugates (ADCs) to treat cancer. This new treatment approach combines a number of technologies to target cancer cells with potent cell-killing agents. Our OGAP® target discovery system – the largest of its type in the world – ‘unlocks’ the power of ADCs by providing a unique range of validated, novel antigen targets identified from a wide range of cancer types

Website: http://www.oxfordbiotherapeutics.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
OX357 / MEN1112monoclonal antibodyAcute Myelogenous Leukemia (AML)Preclinical
Ox025monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)Preclinical
Ox004monoclonal antibodyOvarian cancerPreclinicalSeattle Genetics
Ox025monoclonal antibodySmall Cell Lung Cancer (SCLC)Preclinical
OX076monoclonal antibodyTriple negative Breast cancer PreclinicalImmunogen

View additional information on product candidates here »

Source


http://www.oxfordbiotherapeutics.com/

Recent News Headlines

There are no news items to display